Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

207 recalls, newest first

Class II · Moderate risk

Sertraline Tablets

CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.

Ongoing cGMP deviation Legacy Pharmaceutical Packaging LLC NDC 68645-523-54 D-0205-2024
Class II · Moderate risk

Oxygen

cGMP Deviations

Terminated cGMP deviation Family Medical Supply Inc D-0106-2024
Class III · Low risk

V-FORCE Homeopathic

Incorrect Product Formulation: product contains Active Ingredient Glandula Suprarenalis Suis 8X instead of Glandula Suprarenalis Bovine 8X (as stated on the product label).

Terminated cGMP deviation Grato Holdings, Inc. D-0099-2024
Class II · Moderate risk

Strong Iodine Solution U.S.P.

CGMP Deviations: Recall due to the absence of USP CGMP compendial requirements.

Terminated cGMP deviation Safecor Health, LLC NDC 48433-230-15 D-0082-2024
Class II · Moderate risk

Integrity Biochem HSC 70-VA

CGMP Deviation: Third party test results showing a presence of acetal and acetaldehyde at levels above USP specified amounts.

Terminated cGMP deviation Integrity Bio-Chemicals LLC D-0111-2024
Class II · Moderate risk

Integrity Biochem HSC70-LV

CGMP Deviation: Third party test results showing a presence of acetal and acetaldehyde at levels above USP specified amounts.

Terminated cGMP deviation Integrity Bio-Chemicals LLC D-0110-2024
Class II · Moderate risk

Integrity Biochem HSC 70-LM

CGMP Deviation: Third party test results showing a presence of acetal and acetaldehyde at levels above USP specified amounts.

Terminated cGMP deviation Integrity Bio-Chemicals LLC D-0109-2024
Class II · Moderate risk

Gynazole-1

Incorrect Product Formulation: Hydrophilic Colloidal Silica was used to manufacture the product rather than Hydrophobic Colloidal Silica as required by the manufacturing process.

Ongoing cGMP deviation Padagis US LLC D-0081-2024
Class II · Moderate risk

AstrinGyn (Ferric Subsulfate)

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. NDC 59365-6065-0 D-1101-2023
Class II · Moderate risk

activator concentrate

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. D-1100-2023
Class II · Moderate risk

Unguentine Ointment

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. D-1099-2023
Class II · Moderate risk

Alcolado Relampago

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. D-1098-2023
Class II · Moderate risk

Yager's Liniment

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. D-1097-2023
Class II · Moderate risk

Blis-To-Sol Liquid

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. D-1096-2023
Class II · Moderate risk

Rufinamide Tablets

cGMP deviations: Batch was released prior to approval.

Terminated cGMP deviation Aurobindo Pharma USA Inc. NDC 59651-617-08 D-1088-2023

Recalls by year